CHIP is associated with increased risk of gout. (A) Association between CHIP and gout in the MGBB. Generalized linear model adjusting for age deciles and sex was used to calculate OR and 95% CI. Individuals without CHIP were used as reference group. (B) Association between CHIP and gout in the UKB. Generalized linear model adjusting for age deciles, sex, WBC, eGFR, and BMI was used to calculate OR and 95% CI. Individuals without CHIP were used as reference group. (C) Cumulative incidence of gout in individuals with and without CHIP in UKB. Individuals were identified as events at the time of gout diagnosis and censored at the end of follow-up, at the time of death, or at the time of hematologic malignancy diagnosis. (D) Cumulative incidence of gout among individuals without CHIP and CHIP with VAF <10% in UKB. Individuals were identified as events at the time of gout diagnosis and censored at the end of follow-up, at the time of death, or at the time of hematologic malignancy diagnosis. (E) Cumulative incidence of gout among individuals without CHIP and CHIP with VAF ≥10% in UKB. Individuals were identified as events at the time of gout diagnosis and censored at the end of follow-up, at the time of death, or at the time of hematologic malignancy diagnosis. (F) Forest plot of HR for the association between CHIP and gout in the UKB. Cox proportional hazards model adjusting for age deciles, sex, WBC, eGFR, and BMI was used to calculate HR and 95% CI. Individuals without CHIP were used as reference group.